Week 2 semaglutide at 0.25mg: what TikTok gets right and wrong

What's this video probably claiming?

At 82.9K views, this is exactly the kind of self-injection diary content that floods the GLP-1 corner of TikTok. The creator is documenting week two of semaglutide at the standard 0.25mg starting dose, almost certainly showing the injection process and sharing early impressions. Based on the hashtags and format, the video likely implies that week two is when things start to "work," that appetite suppression is kicking in, and possibly that weight loss results are already visible or measurable. Creators in this genre often frame the first month as a transformation countdown, which sets expectations that the clinical data simply does not support. The caption is brief and the framing is personal, but with 82.9K views, whatever impressions this creator conveys carry real influence on how their audience will interpret their own early semaglutide experience.

What does the science actually show?

The 0.25mg starting dose exists for one reason: tolerability, not weight loss. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) used a 68-week protocol in which participants spent the first four weeks at 0.25mg before escalating toward the 2.4mg maintenance dose. At that maintenance dose, participants achieved a mean body weight reduction of 14.9% versus 2.4% for placebo. That result did not come from 0.25mg. It came from sustained exposure at therapeutic doses over many months. A separate analysis from the STEP 5 trial (Garvey et al., 2022, Nature Medicine) confirmed that meaningful weight loss continued accruing through week 68, with no plateau until well past week 20. Week two at 0.25mg is, pharmacologically speaking, still the warm-up lap. Semaglutide's half-life of approximately one week means steady-state plasma concentrations are not reached until roughly four to five weeks in.

Where does the social media noise diverge from clinical reality?

The gap between TikTok semaglutide content and clinical evidence is widest right here, in weeks one through four. Creators documenting early injections frequently report dramatic appetite suppression, nausea they interpret as "the medication working," and early scale movement they attribute to fat loss. What they are often experiencing is a combination of caloric restriction from nausea, water weight fluctuation, and placebo-influenced behavioral changes. A 2023 analysis in Obesity Reviews (Rubino et al.) noted that patient-reported outcomes in GLP-1 trials showed high variability in early weeks, with some participants experiencing minimal appetite effects at sub-therapeutic doses. The self-injection content genre also routinely omits side effects beyond nausea, including injection site reactions, fatigue, and GI symptoms that affect a meaningful proportion of users in early titration. The FDA-approved prescribing information for Wegovy lists nausea in approximately 44% of trial participants.

What should you actually know?

If you are starting semaglutide and watching content like this for reference, here is what the actual data says. The 0.25mg dose is a titration step, typically held for four weeks before moving to 0.5mg, then continuing upward per your prescriber's protocol. Expecting visible weight loss at week two is not clinically reasonable, and comparing your week two to someone else's week two on TikTok is even less useful, since individual response to GLP-1 agonists varies significantly based on genetics, baseline weight, diet, and other medications. The STEP trials required lifestyle intervention alongside medication, meaning diet and activity were structured components of every participant's protocol, not optional add-ons. Self-injection content that skips that context is leaving out half the mechanism. Work with a licensed provider, follow the titration schedule they prescribe, and give the medication the months it actually needs to reach therapeutic effect.